PCN48 SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH
Abstract
Authors
T Purmonen JA Martikainen EJ Soini V Kataja P Kellokumpu-Lehtinen